Back to today’s briefing

Story perspectives

Novo Nordisk Tops Pfizer's Bid for Metsera

11/4/2025

29 7

Summary

Story summary

Novo Nordisk has bid up to $10 billion for Metsera, while Pfizer has improved its offer to $8.1 billion.
Metsera's board has deemed Novo Nordisk's proposal superior, triggering a two-day window for Pfizer to counter.
Pfizer has filed lawsuits against Metsera and Novo Nordisk, while remaining committed to the acquisition.
Metsera's shares surged nearly 20% amid renewed competition.

1 of 1

Story summary

Novo Nordisk has bid up to $10 billion for Metsera, while Pfizer has improved its offer to $8.1 billion.
Metsera's board has deemed Novo Nordisk's proposal superior, triggering a two-day window for Pfizer to counter.
Pfizer has filed lawsuits against Metsera and Novo Nordisk, while remaining committed to the acquisition.
Metsera's shares surged nearly 20% amid renewed competition.